June 26, 2017 06:45 AM EDT

Seattle Genetics gets a PhIII win for Adcetris, but shares slide as frets linger

John Carroll

Editor & Founder

Seattle Genetics $SGEN has had a rough Q2 as its lead experimental therapy was put back on hold, forcing investigators to scrap Phase III shortly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

Regeneron plans to buy 23andMe for $256M

Trump's health appointees pledge support for cell and gene therapies at FDA roundtable

Anne Wojcicki and Regeneron set to duke it out in restarted 23andMe auction

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...